NCT02583269View on ClinicalTrials.gov

Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 19, 2017

Study Completion Date

April 24, 2023

Conditions
Advanced Malignant NeoplasmMetastatic Malignant NeoplasmUnresectable Malignant Neoplasm
Interventions
DIAGNOSTIC_TEST

Laboratory Biomarker Analysis

Correlative studies

DRUG

Muscadine Grape Skin Extract

Given PO

PROCEDURE

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT02583269 - Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter